Silencing of the polyamine catabolic key enzyme SSAT prevents CDK inhibitor-induced apoptosis in Caco-2 colon cancer cells

Molecular Medicine Reports

Volumn 5, Issue 4, 2012, Pages 1037-1042

  Coker A ^a   Arisan, E D ^a   Palavan Ünsal, Narcin ^a  

^a ISTANBUL KULTUR UNIVERSITY   (Turkey)

Author keywords

Colon carcinoma; Cyclin dependent kinase inhibitors; Polyamines; Purvalanol; Roscovitine; Spermidine spermine N acetyl transferase

Indexed keywords

ACETYLPOLYAMINE OXIDASE; ACYLTRANSFERASE; CYCLIN DEPENDENT KINASE; OXIDOREDUCTASE; POLYAMINE DERIVATIVE; PURVALANOL; ROSCOVITINE; SPERMIDINE SPERMINE N ACETYL TRANSFERASE; SPERMINE OXIDASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; POLYAMINE METABOLISM; PROTEIN EXPRESSION;

ACETYLTRANSFERASES; APOPTOSIS; CACO-2 CELLS; CASPASE 3; CASPASE 9; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASES; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; POLYAMINES; PROTEIN KINASE INHIBITORS; PURINES; PUTRESCINE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SPERMINE;

EID: 84858201928     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.768     Document Type: Article

References (44)

1. Blagden S and de Bono J: Drugging cell cycle kinases in cancer therapy. Curr Drug Targets 6: 325-335, 2005. (Pubitemid 40667798)
2. Chang KH, de Pablo Y, Lee HP, Lee HG, Smith MA and Shah K: Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease. J Neurochem 113: 1221-1229, 2010.
3. Schang LM: Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. Curr Drug Targets Infect Disord 5: 29-37, 2005.
4. Cicenas J and Valius M: The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 137: 1409-1418, 2011.
5. Iseki H, Ko TC, Xue XY, Seapan A, Hellmich MR and Townsend CM Jr: Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Surgery 122: 187-195, 1997. (Pubitemid 27383055)
6. Meijer L, Borgne A, Mulner O, et al: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527-536, 1997. (Pubitemid 27060443)
7. Schutte B, Nieland L, van Engeland M, Henfling ME, Meijer L and Ramaekers FC: The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res 236: 4-15, 1997. (Pubitemid 27452344)
8. Wesierska-Gadek J, Hajek SB, Sarg B, Wandl S, Walzi E and Lindner H: Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells. Biochem Pharmacol 76: 1503-1514, 2008.
9. David-Pfeuty T: Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 18: 7409-7422, 1999.
10. Appleyard MV, O'Neill MA, Murray KE, et al: Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer 124: 465-472, 2009.
11. Ortiz-Ferron G, Yerbes R, Eramo A, Lopez-Perez AI, de Maria R and Lopez-Rivas A: Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res 18: 664-676, 2008. (Pubitemid 351793121)
12. Wesierska-Gadek J, Kramer MP and Maurer M: Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells. Food Chem Toxicol 46: 1327-1333, 2008. (Pubitemid 351258203)
13. Zhang F, Zhang T, Gu ZP, et al: Enhancement of radiosensitivity by roscovitine pretreatment in human non-small cell lung cancer A549 cells. J Radiat Res (Tokyo) 49: 541-548, 2008.
14. Mohapatra S, Chu B, Zhao X, Djeu J, Cheng JQ and Pledger WJ: Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors. Int J Biochem Cell Biol 41: 595-602, 2009.
15. Maurer M, Komina O and Wesierska-Gadek J: Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells. Ann NY Acad Sci 1171: 250-256, 2009.
16. Zolnierczyk JD, Blonski JZ, Robak T, Kilianska ZM and Wesierska-Gadek J: Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide. Ann NY Acad Sci 1171: 124-131, 2009.
17. Iizuka D, Inanami O, Kashiwakura I and Kuwabara M: Purvalanol A enhances cell killing by inhibiting up-regulation of CDC2 kinase activity in tumor cells irradiated with high doses of X rays. Radiat Res 167: 563-571, 2007. (Pubitemid 351292963)
18. Cerquetti L, Sampaoli C, Amendola D, et al: Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation. Int J Oncol 37: 493-501, 2010.
19. Hikita T, Oneyama C and Okada M: Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src. Genes Cells 15: 1051-1062, 2010.
20. Price PM, Yu F, Kaldis P, et al: Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. J Am Soc Nephrol 17: 2434-2442, 2006. (Pubitemid 44300959)
21. Iizuka D, Ogura A, Kuwabara M and Inanami O: Purvalanol A induces apoptosis and downregulation of antiapoptotic proteins through abrogation of phosphorylation of JAK2/STAT3 and RNA polymerase II. Anticancer Drugs 19: 565-572, 2008.
22. Pennati M, Campbell AJ, Curto M, et al: Potentiation of paclitaxel- induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther 4: 1328-1337, 2005.
23. Yenugonda VM, Deb TB, Grindrod SC, et al: Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells. Bioorg Med Chem 19: 2714-2725, 2011.
24. Ringer L, Sirajuddin P, Yenugonda VM, et al: VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biol Ther 10: 320-325, 2010.
25. Marton LJ and Pegg AE: Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol 35: 55-91, 1995.
26. Marton LJ, Pegg AE and Morris DR: Directions for polyamine research. J Cell Biochem 45: 7-8, 1991.
27. Andersson G and Heby O: Kinetics of cell proliferation and polyamine synthesis during Ehrlich ascites tumor growth. Cancer Res 37: 4361-4366, 1977. (Pubitemid 8237954)
28. Heby O, Andersson G and Gray JW: Interference with S and G2 phase progression by polyamine synthesis inhibitors. Exp Cell Res 111: 461-464, 1978. (Pubitemid 8307863)
29. Bachrach U: Polyamines as chemical markers of malignancy. Ital J Biochem 25: 77-93, 1976.
30. Monti MG, Pernecco L, Manfredini R, et al: Inhibition of cell growth by accumulated spermine is associated with a transient alteration of cell cycle progression. Life Sci 58: 2065-2072, 1996. (Pubitemid 26164939)
31. Wang Y and Casero RA Jr: Mammalian polyamine catabolism: a therapeutic target, a pathological problem, or both? J Biochem 139: 17-25, 2006. (Pubitemid 43258842)
32. Casero RA and Pegg AE: Polyamine catabolism and disease. Biochem J 421: 323-338, 2009.
33. Huang Y, Pledgie A, Casero RA Jr and Davidson NE: Molecular mechanisms of polyamine analogs in cancer cells. Anticancer Drugs 16: 229-241, 2005. (Pubitemid 40283938)
34. Chen Y, Weeks RS, Burns MR, Boorman DW, Klein-Szanto A and O'Brien TG: Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Int J Cancer 118: 2344-2349, 2006.
35. Burns MR, Graminski GF, Weeks RS, Chen Y and O'Brien TG: Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor. J Med Chem 52: 1983-1993, 2009.
36. Myhre L, Alm K, Hegardt C, et al: Different cell cycle kinetic effects of N1,N11-diethylnorspermine-induced polyamine depletion in four human breast cancer cell lines. Anticancer Drugs 19: 359-368, 2008.
37. Dredge K, Kink JA, Johnson RM, Bytheway I and Marton LJ: The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer. Cancer Chemother Pharmacol 65: 191-195, 2009.
38. Hector S, Tummala R, Kisiel ND, et al: Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N1, N11 diethylnorspermine. Cancer Chemother Pharmacol 62: 517-527, 2008.
39. Allen WL, McLean EG, Boyer J, et al: The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. Mol Cancer Ther 6: 128-137, 2007. (Pubitemid 46206675)
40. Babbar N, Gerner EW and Casero RA Jr: Induction of spermidine/ spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem J 394: 317-324, 2006. (Pubitemid 43259681)
41. Arisan ED, Coker A and Palavan-Unsal N: Polyamine depletion enhances the roscovitine-induced apoptosis through the activation of mitochondria in HCT116 colon carcinoma cells. Amino Acids: Aug 2, 2011 (E-pub ahead of print).
42. Tirado OM, Mateo-Lozano S and Notario V: Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res 65: 9320-9327, 2005. (Pubitemid 41507999)
43. Varma R, Hector S, Greco WR, et al: Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol 59: 711-723, 2007. (Pubitemid 46440593)
44. 2 in polyamine analogue-treated human breast cancer cell lines. J Biol Chem 280: 39843-39851, 2005.